Navigation Links
FDA Approves Remodulin for Pulmonary Hypertension

According to a notice distributed by the agency, the US Food and Drug Administration (FDA) has approved United Therapeutics Corp.'s pulmonary arterial hypertension therapy Remodulin (treprostinil sodium). A spokesperson for the FDA told Reuters Health that the approved indication covers NYHA class II-IV pulmonary arterial hypertension. The FDA approved the drug under subpart H, which allows for marketing clearance based on an effect// on a surrogate endpoint, provided well-controlled postmarketing studies are conducted.

United Therapeutics received an approvable letter for Remodulin earlier this year after the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-3 in August 2001 to recommend approval.

Remodulin is a synthetic formulation of prostacyclin designed for subcutaneous infusion using a small device developed by Medtronic MiniMed Inc. of Minneapolis, Minnesota.

The drug will compete with GlaxoSmithKline's Flolan (epoprostenol), a synthetic form of prostacyclin delivered via an external pump and an intravenous catheter. United Therapeutics has claimed that Remodulin's delivery system helps reduce the risk of sepsis associated with the delivery of Flolan.


'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/24/2017)... , ... July 24, 2017 , ... A CDC study shows that, although people are ... Caucasians (ages 18 to 29), had at least one case of sunburn within the past ... which causes people to ignore the issue. However, only recently have people become conscientious of ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 NCSL International Workshop ... theme focuses on the new ISO/IEC 17025 standards. This marks the first time ... and calibration will be changed. , As an exhibitor, METTLER TOLEDO will ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited ... plastic surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As ... the world, Allergan is bringing a newly defined structure to the aesthetics market. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... CURE announced that they have enrolled over 100,000 children in their treatment program. ... born every year in areas where treatment is limited or non-existent. Without intervention, ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology: